2nd June, 2023

Jumpstarter 2023 –

Top 100

Delighted to announce that Mindplus AI has been selected as one of the top 100 startups for Jumpstarter 2023! This exciting news is a testament to our commitment and innovative approach to using artificial intelligence and deep learning technology to revolutionize the medical industry.

JUMPSTARTER is a renowned global platform for startups, providing valuable opportunities for entrepreneurs from various fields to showcase their creativity and solutions, and connect with top investors and companies. Being chosen as one of the top 100 startups for Jumpstarter 2023 is a significant milestone for us.

At Mindplus AI, our mission is to improve the accuracy and efficiency of medical diagnosis, particularly in the field of ophthalmology, through the application of AI and deep learning technology. Eye diseases have a significant impact on patients’ vision and quality of life, yet the number of ophthalmology experts is limited in Hong Kong and globally, leading to long waiting times for patients to receive a diagnosis. Our AI module aims to assist medical professionals in quickly and accurately diagnosing abnormal Optical Coherence Tomography (OCT) images and focusing on key regions, thus reducing the waiting time for patients between imaging and diagnosis.

Being selected as one of the top 100 startups for JUMPSTARTER 2023 provides us with an excellent opportunity to showcase the value of our innovative solution to a global audience and establish partnerships with top investors and companies. Our team at Mindplus AI consists of professionals from engineering, business, and medical backgrounds, with expertise in AI development, business operations, financial management, and medical research. We have already completed the initial architecture of our AI module and validated it on public OCT datasets, demonstrating the feasibility of our approach. Our goal is to provide an innovative solution to the existing problem of long waiting times and a shortage of ophthalmology experts in Hong Kong, improving the accuracy and efficiency of OCT diagnosis and ultimately benefiting patients and society through technology.